Cours suspendu

Communiqués Oncternal Therapeutics, Inc.

Actions

ONCT

US68236P2065

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/12/2024			Varia. 5j.	Varia. 1 janv.
0,5266 ^USD	-24,11%		-.--%	-

01/07/25	Craig R. Jalbert nommé PDG d'Oncternal Therapeutics, Inc.	CI
01/07/25	Oncternal Therapeutics, Inc. annonce des changements au sein de sa direction	CI

Communiqués

07/03/25	Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC	AQ
25/11/24	Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K	PU
22/10/24	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
12/09/24	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives	AQ
08/08/24	Oncternal Therapeutics: Q2 Earnings Snapshot	AQ
08/08/24	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results	AQ
01/08/24	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results	AQ
16/07/24	Oncternal Therapeutics : Corporate Presentation, July 2024	PU
15/07/24	Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
11/07/24	Oncternal Therapeutics to Present in JonesTrading Healthcare Summit	AQ
14/06/24	M. Wang 2024 EHA Poster: A Multi Center, Open Label, Phase 1/2 Study of ONCT 808, A ROR1 Targeting CAR T Cell Therapy, in Adults with Relapsed/Refractory Aggressive B Cell Lymphomas	PU
31/05/24	Oncternal Therapeutics : Corporate Presentation, June 2024	PU
30/05/24	Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
11/05/24	Oncternal Therapeutics : Corporate Presentation, May 2024	PU
09/05/24	Oncternal Therapeutics: Q1 Earnings Snapshot	AQ
09/05/24	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results	AQ
02/05/24	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results	AQ
01/05/24	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	AQ
18/04/24	Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
15/03/24	Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer	AQ
07/03/24	Oncternal Therapeutics: Q4 Earnings Snapshot	AQ
07/03/24	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	AQ
29/02/24	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results	AQ
06/02/24	Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ
01/02/24	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	AQ